Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab plus verteporfin photodynamic therapy versus ranibizumab alone for myopic choroidal neovascularization
2008-000544-13Phase 4Active
- Sponsor
- Hospital Clínico San Carlos
- Start
- Feb 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ranibizumab and verteporfin in myopic choroidal neovascularisation (mCNV) (2 arms), sponsored by Hospital Clínico San Carlos. Primary endpoints: Best corrected distance visual acuity and Number of ranibizumab retreatments. Started Feb 2008; status: active.
02
Drugs
ranibizumabverteporfin
03
Conditions
myopic choroidal neovascularisation (mCNV)
Beyond the preview
Go deeper on 2008-000544-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000544-13.